Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12633845 | 0.91 | P2RY14 (0.48) | P2RY14TTRMAPTMMP12ALDH1A1 | |
| SCHEMBL1880854 | 0.84 | TTR (0.54) | TTRMAPTMMP12ALDH1A1POLB | |
| SCHEMBL1876553 | 0.83 | P2RY14 (0.48) | P2RY14MAPTMMP12ALDH1A1POLB | |
| SCHEMBL1878215 | 0.79 | MMP12 (0.44) | P2RY14MAPTMMP12ALDH1A1POLB | |
| SCHEMBL29505633 | 0.78 | CYP2A6 (0.47) | P2RY14MAPTMMP12ALDH1A1HDAC1 | |
| SCHEMBL1160196 | 0.78 | CYP2A6 (0.47) | P2RY14MAPTMMP12ALDH1A1HDAC1 | |
| SCHEMBL12633819 | 0.77 | MMP12 (0.56) | P2RY14TTRMAPTMMP12ALDH1A1 | |
| SCHEMBL30277224 | 0.76 | TTR (0.53) | TTRMAPTALDH1A1GAAKDM4E | |
| SCHEMBL12633811 | 0.74 | P2RY14 (0.57) | P2RY14MAPTMMP12ALDH1A1HDAC1 | |
| SCHEMBL29953448 | 0.74 | P2RY14 (0.57) | P2RY14MAPTMMP12ALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
| EP-1943226-A2 | PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007047397-A2 | PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | OPRK1, OPRL1, OPRD1 | P2RY14 470/4885TTR 4804/4885MAPT 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.